X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6826) 6826
Magazine Article (8) 8
Book Review (2) 2
Book Chapter (1) 1
Dissertation (1) 1
Newsletter (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5780) 5780
female (3515) 3515
quinazolines - administration & dosage (3273) 3273
male (3194) 3194
oncology (3053) 3053
middle aged (2404) 2404
quinazolines - therapeutic use (2316) 2316
aged (2123) 2123
animals (2035) 2035
quinazolines - pharmacology (1989) 1989
adult (1830) 1830
lung neoplasms - drug therapy (1624) 1624
quinazolines - adverse effects (1464) 1464
gefitinib (1457) 1457
antineoplastic combined chemotherapy protocols - therapeutic use (1433) 1433
carcinoma, non-small-cell lung - drug therapy (1361) 1361
erlotinib hydrochloride (1308) 1308
treatment outcome (1284) 1284
cancer (1279) 1279
chemotherapy (1221) 1221
receptor, epidermal growth factor - antagonists & inhibitors (1121) 1121
mice (1103) 1103
antineoplastic agents - therapeutic use (1071) 1071
erlotinib (1045) 1045
pharmacology & pharmacy (1011) 1011
cell line, tumor (907) 907
lung neoplasms - pathology (794) 794
dose-response relationship, drug (785) 785
care and treatment (769) 769
mutation (762) 762
aged, 80 and over (759) 759
growth-factor receptor (719) 719
tyrosine kinase inhibitor (710) 710
receptor, epidermal growth factor - genetics (705) 705
epidermal growth factor (696) 696
protein kinase inhibitors - therapeutic use (684) 684
antineoplastic agents - administration & dosage (671) 671
quinazolines - pharmacokinetics (663) 663
egfr (647) 647
research (633) 633
rats (622) 622
breast neoplasms - drug therapy (618) 618
expression (617) 617
carcinoma, non-small-cell lung - pathology (615) 615
antineoplastic agents - pharmacology (610) 610
disease-free survival (584) 584
lung neoplasms - genetics (576) 576
protein kinase inhibitors - administration & dosage (572) 572
lung cancer, non-small cell (562) 562
therapy (561) 561
medicine & public health (556) 556
lung cancer (553) 553
receptor, epidermal growth factor - metabolism (552) 552
antineoplastic agents - adverse effects (548) 548
analysis (532) 532
administration, oral (529) 529
cell lung-cancer (526) 526
antineoplastic combined chemotherapy protocols - adverse effects (524) 524
hematology, oncology and palliative medicine (522) 522
drug administration schedule (521) 521
adenocarcinoma - drug therapy (501) 501
drug therapy (492) 492
neoplasm staging (485) 485
carcinoma, non-small-cell lung - genetics (483) 483
protein kinase inhibitors - pharmacology (477) 477
cell proliferation - drug effects (467) 467
breast cancer (462) 462
deoxycytidine - analogs & derivatives (454) 454
tumors (445) 445
trial (441) 441
lapatinib (435) 435
trastuzumab (428) 428
combination (427) 427
apoptosis (425) 425
apoptosis - drug effects (423) 423
survival (417) 417
tyrosine (410) 410
respiratory system (396) 396
deoxycytidine - administration & dosage (394) 394
metastasis (392) 392
time factors (384) 384
signal transduction - drug effects (383) 383
xenograft model antitumor assays (382) 382
prognosis (377) 377
antibodies, monoclonal, humanized (371) 371
clinical trials (369) 369
breast neoplasms - pathology (362) 362
protein kinase inhibitors - adverse effects (361) 361
pharmacokinetics (357) 357
kinases (356) 356
mutations (355) 355
drug resistance, neoplasm (352) 352
antineoplastic agents (347) 347
mice, nude (346) 346
non-small cell lung cancer (343) 343
neoplasms - drug therapy (341) 341
clinical trials as topic (339) 339
epidermal growth factor receptor (339) 339
bevacizumab (337) 337
fluorouracil - administration & dosage (330) 330
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6512) 6512
Japanese (151) 151
Chinese (74) 74
German (55) 55
French (54) 54
Russian (28) 28
Spanish (26) 26
Italian (19) 19
Czech (12) 12
Hungarian (11) 11
Polish (8) 8
Danish (3) 3
Finnish (3) 3
Norwegian (3) 3
Bulgarian (2) 2
Ukrainian (2) 2
Korean (1) 1
Portuguese (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie and the Associazione Italiana Oncologia Toracica and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 05/2015, Volume 45, Issue 5, pp. 408 - 410
Several 'lines of therapy' that utilize cytotoxic agents and are driven by platinum-free intervals are the current standard of care for patients with recurrent... 
Chemo-gynecology | Molecular Dx | Gynecol-med | PEGYLATED LIPOSOMAL DOXORUBICIN | CARBOPLATIN | gynecol-med | BEVACIZUMAB | molecular Dx | COMBINATION | CHEMOTHERAPY | PACLITAXEL | PHASE-III TRIAL | THERAPY | ONCOLOGY | DOUBLE-BLIND | PROGRESSION | chemo-gynecology | Piperazines - administration & dosage | Humans | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Folic Acid - administration & dosage | TOR Serine-Threonine Kinases - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - administration & dosage | Vinca Alkaloids - administration & dosage | Benzimidazoles - administration & dosage | Doxorubicin - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Antimetabolites, Antineoplastic - pharmacology | Female | Quinazolines - administration & dosage | Antineoplastic Agents - pharmacology | Paclitaxel - administration & dosage | Everolimus | Ovarian Neoplasms - drug therapy | Recombinant Fusion Proteins - administration & dosage | Doxorubicin - administration & dosage | Sirolimus - analogs & derivatives | Folic Acid - analogs & derivatives | Phthalazines - administration & dosage | Pyrimidines - administration & dosage | Deoxycytidine - administration & dosage | Angiogenesis Inhibitors - pharmacology | Carboplatin - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors | Polyethylene Glycols - administration & dosage | Sirolimus - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Nivolumab | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Topotecan - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | SAFETY | ERBB2 | INHIBITOR | COMBINATION | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Lapatinib | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Ultrasonic imaging | Surgery | Diarrhea | Cytotoxicity | Ligands | Cancer therapies | Tumors | Medical research | Mammography | Kinases | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2014, Volume 32, Issue 19, pp. 2078 - 2099
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2012, Volume 30, Issue 10, pp. 1122 - 1128
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2009, Volume 27, Issue 33, pp. 5538 - 5546
Purpose Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial... 
EFFICACY | ONCOLOGY | RANDOMIZED PHASE-II | TAMOXIFEN RESISTANCE | GROWTH | MCF-7 CELLS | COMBINATION | INHIBITOR | EXPRESSION | ESTROGEN-RECEPTOR | PLUS | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2012, Volume 30, Issue 26, pp. 3234 - 3241
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | THERAPY | NSCLC | ONCOLOGY | ADENOCARCINOMA | OPEN-LABEL | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1183 - 1192
... at surgery. Recently the US Food and Drug Administration (FDA) in collaboration with an international working group undertook a large meta-analysis of 12 993 patients... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | WOMEN | CELLS | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | GW572016 | CHEMOTHERAPY PLUS TRASTUZUMAB | PERTUZUMAB | INHIBITOR | DOCETAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Puerto Rico | United States | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Mastectomy | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Drug Administration Schedule | Logistic Models | Treatment Outcome | Chi-Square Distribution | Breast Neoplasms - drug therapy | Canada | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Quinazolines - adverse effects | Trastuzumab | Health maintenance organizations | Neoadjuvant therapy | Medical colleges | Care and treatment | Cyclophosphamide | Anthracyclines | Adjuvant treatment | Breast cancer | Product development | Public health | Cancer | Index Medicus
Journal Article